American Society of Hirudotherapy

Revisiting antithrombotic therapeutics; sculptin, a novel specific, competitive, reversible, scissile and tight binding inhibitor of thrombin

Research article published in Scientific reports (2017)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportDrug DevelopmentIqbal A et al. · Scientific reports, 2017

Abstract

Thrombin is a multifunctional enzyme with a key role in the coagulation cascade. Its functional modulation can culminate into normal blood coagulation or thrombosis. Thus, the identification of novel potent inhibitors of thrombin are of immense importance. Sculptin is the first specific thrombin inhibitor identified in the transcriptomics analysis of tick's salivary glands. It consists of 168 residues having four similar repeats and evolutionary diverged from hirudin. Sculptin is a competitive, specific and reversible inhibitor of thrombin with a Ki of 18.3 ± 1.9 pM (k on 4.04 ± 0.03 × 107 M-1 s-1 and k off 0.65 ± 0.04 × 10-3 s-1). It is slowly consumed by thrombin eventually losing its activity. Contrary, sculptin is hydrolyzed by factor Xa and each polypeptide fragment is able to inhibit thrombin independently. A single domain of sculptin alone retains ~45% of inhibitory activity, which could bind thrombin in a bivalent fashion. The formation of a small turn/helical-like structure by active site binding residues of sculptin might have made it a more potent thrombin inhibitor. In addition, sculptin prolongs global coagulation parameters. In conclusion, sculptin and its independent domain(s) have strong potential to become novel antithrombotic therapeutics.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsBinding, CompetitiveBlood CoagulationCatalytic DomainCrystallography, X-RayFactor XaFibrinolytic AgentsGene ExpressionHirudinsHumansHydrolysisIxodidae

Summary

Revisiting antithrombotic therapeutics; sculptin, a novel specific, competitive, reversible, scissile and tight binding inhibitor of thrombin.

Why This Matters for Hirudotherapy

This study characterizes sculptin, a novel thrombin inhibitor identified from tick salivary gland transcriptomics, as a competitive, specific, reversible inhibitor (Ki ~18.3 pM) that is evolutionarily diverged from hirudin and prolongs global coagulation parameters. The abstract distinguishes that thrombin slowly consumes sculptin (eventually losing its activity), whereas factor Xa hydrolyzes it, with each polypeptide fragment able to inhibit thrombin independently. Relevance to ASH is indirect: sculptin is tick-derived and not leech-derived, though it is explicitly compared to hirudin and discussed within the antithrombotic therapeutic landscape. Caveat: the study involves no leeches and reports laboratory findings without clinical data.

Citation

Revisiting antithrombotic therapeutics; sculptin, a novel specific, competitive, reversible, scissile and tight binding inhibitor of thrombin

Iqbal A et al. · Scientific reports, 2017

DOI

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.